GUTS - Total Utang marang Modal Fractyl Health, Inc

Logo perusahaan publik Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. (GUTS) is developing innovative gene therapies to combat diabetes and obesity, leveraging the potential of the Rejuvenate system and interest from corporate behemoths. Simultaneously, the business is implementing ESG principles by optimizing energy costs and research ethics. The verified price history on the GURU.Markets platform chart reflects a debt-to-equity ratio of 0.00, complemented by the full capacity utilization of its own modernized plants.

GUTS: Total Utang marang Modal Fractyl Health 21.02.2024 - 30.10.2026

Rincian analitis perusahaan Fractyl Health, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Fractyl Health|GUTS - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Fractyl Health|GUTS - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Fractyl Health|GUTS - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku fractyl.com|GUTS - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Fractyl Health, Inc.|GUTS - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Fractyl Health, Inc.|GUTS - Gunggung utang perusahaan|Utang marang nilai buku Fractyl Health|GUTS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Fractyl Health|Rasio cepet fractyl.com
- informasi bathi lan kelipatan valuasi:
GUTS - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Fractyl Health
Barang utama Fractyl Health, Inc

Developing an innovative mucosal regeneration method for diabetes treatment requires significant capital investment in a technological moat for Fractyl Health, Inc. (GUTS). Analyzing the debt-to-equity chart, an investor assesses the proportion of total liabilities to net assets, which determines the degree of financial leverage and the stability of the business's funding structure in the face of market volatility.

Analisis pesaing Fractyl Health, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal BMEA|Utang marang Ekuitas QNCX (quincetx.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Total Utang marang Modal ONVO (Organovo Holdings, Inc.)|RDUS (radiuspharm.com) - Utang Agregat marang Ekuitas